FUJIFILM Holdings sets its highest record with 24 products winning the internationally prestigious “iF Design Award”

- Recognized for beautiful appearance, advanced performance and excellent operability in products of various business fields

FUJIFILM Holdings Corporation (President and CEO, Representative Director: Teiichi Goto) is pleased to announce that its products in a wide range of business fields including mirrorless digital cameras, ultrasound diagnostic devices and cosmetics, have been awarded the “iF Design Award 2022,” sponsored by the iF International Forum Design based in Hannover, Germany.

FUJIFILM Holdings sets its highest record with 24 products*1 winning the prestigious award in recognition of not only the products’ beautiful appearance but also their design that achieves advanced performance and excellent operability.

The iF Design Award is a prestigious international design award launched in 1953, and is considered one of the top three global design awards, alongside “Red Dot Design Award” in Germany and “International Design Excellence Awards (IDEA)” in the United States. This year, there were approximately 11,000 entries from 57 countries and regions around the world.

In developing all of its products and services, FUJIFILM Holdings not only pursues functionality and performance, but also strives to develop designs that bring out the best of the advanced functionality and performance. The company will continue to work on creating design that have beautiful appearance and reflects commitment to offering operability for ease of use and comfort, thereby creating new product values.

_{*1 Including a facility and sales promotion tools.}

_{* Please note that the contents including the product availability, specification, prices and contacts in this website are current as of the date of the press announcement and may be subject to change without prior notice.}

_{* This news release is issued by FUJIFILM Holdings Corporation in Japan. Fujifilm makes no representation that products on this news release are commercially available in all countries and regions（including US and EU). Approved uses of healthcare products vary by country and region.}